Literature DB >> 19640720

Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic efficacy against morphine dependence.

Ishani Deb1, Priyankar Paira, Abhijit Hazra, Sukdeb Banerjee, Pradip Kumar Dutta, Nirup Bikash Mondal, Sumantra Das.   

Abstract

Based on an established 3D pharmacophore, a series of quinoline derivatives were synthesized. The opioidergic properties of these compounds were determined by a competitive binding assay using (125)I-Dynorphine, (3)H-DAMGO and (125)I-DADLE for kappa, mu, and delta receptors, respectively. Results showed varying degree of activities of the compounds to kappa and mu opioid receptors with negligible interactions at the delta receptor. The compound, S4 was the most successful in inhibiting the two most prominent quantitative features of naloxone precipitated withdrawal symptoms - stereotyped jumping and body weight loss. Determination of IC(50) of S4 revealed a greater affinity towards mu compared to kappa receptor. In conclusion, quinoline derivatives of S4 like structure offer potential tool for treatment of narcotic addictions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19640720     DOI: 10.1016/j.bmc.2009.07.024

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis.

Authors:  Partha Palit; Abhijit Hazra; Arindam Maity; R S K Vijayan; Prabu Manoharan; Sukdeb Banerjee; Nirup B Mondal; Nanda Ghoshal; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

2.  Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy.

Authors:  Aubrie A Harland; Irina D Pogozheva; Nicholas W Griggs; Tyler J Trask; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Neurosci       Date:  2017-08-25       Impact factor: 4.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.